View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEmbecta 향후 성장Future 기준 점검 3/6Embecta은 연간 수입과 매출이 각각 28.4%와 0.3% 증가할 것으로 예상되고 EPS는 연간 32.9%만큼 증가할 것으로 예상됩니다.핵심 정보28.4%이익 성장률32.88%EPS 성장률Medical Equipment 이익 성장0%매출 성장률0.3%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트09 Aug 2023최근 향후 성장 업데이트공시 • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.공시 • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.공시 • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.공시 • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.공시 • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.공시 • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.모든 업데이트 보기Recent updates공시 • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.공시 • Dec 19Embecta Corp., Annual General Meeting, Feb 11, 2026Embecta Corp., Annual General Meeting, Feb 11, 2026.공시 • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.공시 • Nov 18Embecta Corp. Announces Board ChangesEmbecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.공시 • Nov 12Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025공시 • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.공시 • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.공시 • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.공시 • Apr 22Embecta Corp. to Report Q2, 2025 Results on May 09, 2025Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025공시 • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.공시 • Jan 24Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025공시 • Dec 20Embecta Corp., Annual General Meeting, Feb 12, 2025Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United States공시 • Dec 03Embecta Corp. Announces Executive ChangesEmbecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer.공시 • Dec 01Embecta Corp. announced delayed annual 10-K filingOn 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.공시 • Nov 13Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024공시 • Sep 03Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery SystemEmbecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.공시 • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.공시 • Jul 19Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024공시 • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.공시 • Apr 24Embecta Corp. to Report Q2, 2024 Results on May 09, 2024Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024공시 • Feb 09+ 1 more updateEmbecta Corp. Updates Earnings Guidance for the Fiscal Year 2024Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.공시 • Jan 25Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024공시 • Jan 09Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch PumpEmbecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.공시 • Dec 20Embecta Corp., Annual General Meeting, Feb 07, 2024Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan.공시 • Nov 22+ 2 more updatesEmbecta Corp. to Report Q4, 2023 Results on Nov 21, 2023Embecta Corp. announced that they will report Q4, 2023 results on Nov 21, 2023공시 • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2023Embecta Corp. revised earnings guidance for the fiscal year 2023. For the year, company expects revenue $1,107 Million to $1,113 Million against previous guidance for revenue to be in range of $1,101 Million to $1,113 Million.공시 • Jul 06Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023.Reported Earnings • May 17Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 9.1% growth forecast for the Global Medical Equipment industry.Board Change • May 17High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • May 13+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Fiscal Year 2023Embecta Corp. revises revenue guidance for the fiscal year 2023. The company now expects revenue of $1,101 million- $1,113 million against previous forecast of $1,084 million - $1,107 million.공시 • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.Reported Earnings • Feb 15First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 8.7% growth forecast for the Global Medical Equipment industry.Board Change • Jan 30High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Jan 25Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023Board Change • Jan 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 22% share price gain to Mex$666, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 25x in the Medical Equipment industry globally.Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Oct 01Embecta Corp., Annual General Meeting, Feb 09, 2023Embecta Corp., Annual General Meeting, Feb 09, 2023.Reported Earnings • Aug 16Third quarter 2022 earnings releasedThird quarter 2022 results: Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 2.5% compared to a 19% growth forecast for the Medical Equipment industry in Mexico.공시 • Jul 06Embecta Corp. to Report Q3, 2022 Results on Aug 15, 2022Embecta Corp. announced that they will report Q3, 2022 results Pre-Market on Aug 15, 2022공시 • May 14Embecta Corp. Provides Revenue Guidance for the Last Six Months of Fiscal Year 2022Embecta Corp. provided revenue guidance for the last six months of fiscal year 2022. For the period, the company expects total revenue of approximately $555 million, representing a decrease of approximately 7.0%, as compared to total revenue of $596 million for the last six months of fiscal year 2021.공시 • Apr 20Embecta Corp. to Report Q2, 2022 Results on May 13, 2022Embecta Corp. announced that they will report Q2, 2022 results Pre-Market on May 13, 2022이익 및 매출 성장 예측BMV:EMBC * - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/20251,121139N/AN/A29/30/20241,115127N/AN/A39/30/20231,110118N/AN/A36/30/20231,114477096N/A3/31/20231,11994114138N/A12/31/20221,116160309334N/A9/30/20221,130224388412N/A6/30/20221,156338411440N/A3/31/20221,160380506537N/A12/31/20211,169408442474N/A9/30/20211,165415417456N/A9/30/20201,086428457499N/A9/30/20191,109432436505N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: EMBC * 의 연간 예상 수익 증가율(28.4%)이 saving rate(7.6%)보다 높습니다.수익 vs 시장: EMBC * 의 연간 수익(28.4%)이 MX 시장(9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: EMBC * 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: EMBC * 의 수익(연간 0.3%)이 MX 시장(연간 6.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: EMBC * 의 수익(연간 0.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: EMBC *의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/08/13 02:41종가2023/05/16 00:00수익2023/06/30연간 수익2022/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Embecta Corp.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Travis SteedBofA Global ResearchTravis SteedBofA Global ResearchMichael GormanBTIG4명의 분석가 더 보기
공시 • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.
공시 • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.
공시 • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.
공시 • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.
공시 • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.
공시 • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.
공시 • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.
공시 • Dec 19Embecta Corp., Annual General Meeting, Feb 11, 2026Embecta Corp., Annual General Meeting, Feb 11, 2026.
공시 • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.
공시 • Nov 18Embecta Corp. Announces Board ChangesEmbecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.
공시 • Nov 12Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025
공시 • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.
공시 • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.
공시 • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.
공시 • Apr 22Embecta Corp. to Report Q2, 2025 Results on May 09, 2025Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025
공시 • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.
공시 • Jan 24Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025
공시 • Dec 20Embecta Corp., Annual General Meeting, Feb 12, 2025Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United States
공시 • Dec 03Embecta Corp. Announces Executive ChangesEmbecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer.
공시 • Dec 01Embecta Corp. announced delayed annual 10-K filingOn 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.
공시 • Nov 13Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024
공시 • Sep 03Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery SystemEmbecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
공시 • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.
공시 • Jul 19Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024
공시 • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.
공시 • Apr 24Embecta Corp. to Report Q2, 2024 Results on May 09, 2024Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024
공시 • Feb 09+ 1 more updateEmbecta Corp. Updates Earnings Guidance for the Fiscal Year 2024Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.
공시 • Jan 25Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024
공시 • Jan 09Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch PumpEmbecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
공시 • Dec 20Embecta Corp., Annual General Meeting, Feb 07, 2024Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan.
공시 • Nov 22+ 2 more updatesEmbecta Corp. to Report Q4, 2023 Results on Nov 21, 2023Embecta Corp. announced that they will report Q4, 2023 results on Nov 21, 2023
공시 • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2023Embecta Corp. revised earnings guidance for the fiscal year 2023. For the year, company expects revenue $1,107 Million to $1,113 Million against previous guidance for revenue to be in range of $1,101 Million to $1,113 Million.
공시 • Jul 06Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023.
Reported Earnings • May 17Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 9.1% growth forecast for the Global Medical Equipment industry.
Board Change • May 17High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • May 13+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Fiscal Year 2023Embecta Corp. revises revenue guidance for the fiscal year 2023. The company now expects revenue of $1,101 million- $1,113 million against previous forecast of $1,084 million - $1,107 million.
공시 • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.
Reported Earnings • Feb 15First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 8.7% growth forecast for the Global Medical Equipment industry.
Board Change • Jan 30High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Jan 25Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023
Board Change • Jan 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 22% share price gain to Mex$666, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 25x in the Medical Equipment industry globally.
Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Oct 01Embecta Corp., Annual General Meeting, Feb 09, 2023Embecta Corp., Annual General Meeting, Feb 09, 2023.
Reported Earnings • Aug 16Third quarter 2022 earnings releasedThird quarter 2022 results: Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 2.5% compared to a 19% growth forecast for the Medical Equipment industry in Mexico.
공시 • Jul 06Embecta Corp. to Report Q3, 2022 Results on Aug 15, 2022Embecta Corp. announced that they will report Q3, 2022 results Pre-Market on Aug 15, 2022
공시 • May 14Embecta Corp. Provides Revenue Guidance for the Last Six Months of Fiscal Year 2022Embecta Corp. provided revenue guidance for the last six months of fiscal year 2022. For the period, the company expects total revenue of approximately $555 million, representing a decrease of approximately 7.0%, as compared to total revenue of $596 million for the last six months of fiscal year 2021.
공시 • Apr 20Embecta Corp. to Report Q2, 2022 Results on May 13, 2022Embecta Corp. announced that they will report Q2, 2022 results Pre-Market on May 13, 2022